FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

TATEMENT	OF CHA	NGES IN	BENEFICIAL	OWNERSHIP

l	OMB APPRO	VAL			
	OMB Number:	3235-0287			
	Estimated average burde	en			
l	hours per response:	0.5			

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person* <u>Richman Michael</u>					2. Issuer Name and Ticker or Trading Symbol PIERIS PHARMACEUTICALS, INC. [PIRS]									5. Relationship of Reporting Person(s) to Issuer (Check all applicable) X Director 10% Owner					
	RIS PHARI	MACEUTICAL	(Middle) S, INC.		3. Date of Earliest Transaction (Month/Day/Year) 01/25/2019									Offi belo	cer (give title w)		Other (s below)	specify	
255 STATE STREET, 9TH FLOOR					4. If Amendment, Date of Original Filed (Month/Day/Year)								6.	6. Individual or Joint/Group Filing (Check Applicable					
(Street) BOSTON MA 02109													Line) X Form filed by One Reporting Person Form filed by More than One Reporting Person						
(City) (State) (Zip)																			
		Tab	le I - Non	-Deriva	ative	Se	curities	Ac	quired, D	isp	osed o	f, or Be	neficia	ly Own	ed				
1. Title of Security (Instr. 3) 2. Transac Date (Month/Date)			Date	Execution Date,		3. Transaction Code (Instr. 8) 4. Securities Acquired (A) Disposed Of (D) (Instr. 3, 4) 5)			Secur Bene Owne	icially d Following	Form (D) o	Ownership orm: Direct o) or Indirect (Instr. 4)	7. Nature of Indirect Beneficial Ownership						
					Code V	,	Amount	unt (A) or Pi		Repo Trans (Instr	ted action(s) 3 and 4)			(Instr. 4)					
	Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)																		
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security 3. Transaction Date Execution Date, if any (Month/Day/Year) (Month/Day/Year) 3. Transaction Execution Date, if any (Month/Day/Year) (Month/Day/Year)		ansaci	ction of E			6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price Derivati Security (Instr. 5)	e derivativ	e s ally g	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)				
				Co	ode \	v	(A)	(D)	Date Exercisable		opiration	Title	Amount or Number of Shares						
Stock Option (right to buy)	\$2.74	01/25/2019			A		6,096		01/25/2019	01	/25/2029	Common Stock	6,096	\$1.79 ⁽¹	6,09	6	D		
Stock Option (right to buy)	\$2.74	01/25/2019			A		20,000		(2)	01	/25/2029	Common Stock	20,000	\$0.00	20,00	00	D		

Explanation of Responses:

- 1. The stock option was issued to the Reporting Person, who elected to take stock options in lieu of \$10,937.50 in cash compensation for services as a director and committee member, which compensation is payable to the Reporting Person quarterly in arrears, pursuant to the Issuer's non-employee director compensation policy.
- 2. The stock option will vest as to 100% of the underlying shares on January 25, 2020, subject to the Reporting Person's continued service as a director through the vesting date.

Remarks:

/s/ Marc D. Mantell, Attorney-01/29/2019 in-fact

** Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.